Enlivex
Manufacturing · Israel · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Weizmann Science Park 14, Ness Ziona, Ce...Phone Number
+972 86328500Website
www.enlivex.comRevenue
$7.6 MillionStock Symbol
ENLVIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Enlivex
Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve hyper-expression of cytokines (Cytokine Release Syndrome) and for which there are no approved treatments (unmet medical needs) such as sepsis and COVID-19, as well as solid tumors' immune-checkpoint rebalancing.Explore more
Enlivex Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Enlivex your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Enlivex, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Enlivex
Check out if Enlivex is spiking on competitors!
Check if Enlivex has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Enlivex launches new products
Earning: See what the market has to say on Enlivex recently announced quarterly report
Click to see if Enlivex had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Enlivex has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Enlivex is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Enlivex is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Enlivex.
Enlivex financials insights
Gather financial insights about Enlivex, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Debt
$7M
2025
Stock/Share Issuance
$212M
2026
Debt
$21M
Enlivex Tech Stack
A closer look at the technologies used by Enlivex
See more technologies
Most Recent Scoops
Project
Product Development, Product Management, Intellectual Property, Legal Affairs, Pharmaceuticals
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
Enlivex News & Media
Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.14 Billion
Nes-Ziona, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, "Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today provided an update on its RAIN token holdings. As of June 20, 2026, the Company held 79,568,550,005 RAIN tokens with a total value of approximately $1.14 billion1.Enlivex Announces Issuance of Australian Patent Covering the Use of Allocetra™ in Patients with Osteoarthritis
Nes-Ziona, Israel, June 15, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced the issuance of an Australian patent, numbered 2020340629, titled, “THERAPEUTIC APOPTOTIC CELLS FOR TREATMENT OF OSTEOARTHRITIS”. The patent will provide Enlivex with added intellectual property protection in Australia through at least 2040 with claims covering methods of using Allocetra™ to treat subjENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2026
As a Gold Sponsor of the Paris event, Enlivex will host a curated dinner today for leading institutional asset managers, allocators, and digital asset investorsAllocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026
Nes-Ziona, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, "Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced that it will present at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology, taking place June 3-7, 2026, in London, UK.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Enlivex
Sign Up For FreeTo access detailed company insights
Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve hyper-expression of cytokines (Cytokine Release Syndrome) and for which there are no approved treatments... Read More
